title: Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma.
abstract: BACKGROUND
  Cocaine-induced myocardial infarction (MI) is well documented. Current literature recommends avoiding beta-blockers in the acute care setting, but after discharge from the hospital, benefits of beta-blocker use may outweigh risks in patients with recent MI resulting from cocaine use. Cardioselective beta-blocker therapy has been demonstrated to be beneficial in post-MI patients with nonsevere asthma. This review article is to compare the risks and benefits of using carvedilol in patients with asthma who have had cocaine-induced MI.
  
  
  METHODS
  The authors searched the English literature from 1984 to July 2010 via PubMed, EMBASE and SCOPUS using the following search terms: "cocaine-induced myocardial infarction AND treatment," "cocaine AND carvedilol," "beta blockers AND asthma," and "carvedilol AND asthma." All studies and case reports related to carvedilol use associated with bronchospasm in patients with asthma and carvedilol use after cocaine-induced MI were included.
  
  
  RESULTS
  Carvedilol has theoretical advantages in patients who use cocaine, but there are no controlled studies confirming the superior efficacy of this agent. Reports of carvedilol use in patients with asthma are rare, but findings include increased asthma symptoms and hospitalization in some patients. Fatal asthma has also been reported because of this noncardioselective beta-blocker.
  
  
  CONCLUSIONS
  Based on a lack of evidence supporting the theoretical advantages but documented risks associated with its use in patients with asthma, carvedilol should be avoided in asthma patients who have a history of cocaine-induced MI. Cardioselective beta-blockers should be used in post-MI patients with nonsevere asthma.
authors.affiliation: Department of Clinical Pharmacy, University of Tennessee Health Science Center, Methodist University Hospital, University of Tennessee Health Science Center Memphis, Tennessee 38163, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Self
authors.forename: Maegan L
authors.initials: ML
authors.lastname: Rogers
authors.forename: Jimmie
authors.initials: J
authors.lastname: Mancell
authors.forename: Judith E
authors.initials: JE
authors.lastname: Soberman
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use; D001249:Asthma / Q000150:complications*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D002986:Clinical Trials as Topic; D003042:Cocaine / Q000009:adverse effects*; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000150:complications* / Q000188:drug therapy; D011412:Propanolamines / Q000627:therapeutic use*; D012107:Research Design; D012306:Risk; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000009:adverse effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D002227:Carbazoles; D011412:Propanolamines; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000077261:Carvedilol; D003042:Cocaine